FDA Flexible CMC Requirements for Cell and Gene Therapies: What Sponsors Need to Know

In this blog, Moira Frances explores the FDA’s formalization of a flexible CMC framework for cell and gene therapies, examining what has changed and how sponsors can apply this approach to de-risk development and support successful BLA submissions.

With its January 2026 announcement, the FDA has finally put in writing its flexible approach to CMC requirements for cell and gene therapies (CGTs). This is a meaningful shift toward consistency and transparency, aiming to reduce uncertainty for developers and streamline the path from early-stage trials to BLA submission. In this blog, we highlight key points and what it means for Sponsors.

In January 2026, the FDA formally announced that CBER reviewers will consistently apply a flexible CMC framework to cell and gene therapy (CGT) programs as they progress toward BLA submission.

While regulatory flexibility is not new, nor unique to CGT (the same principle has also been applied in expedited development and review wettings for products addressing unmet medical needs in serious or life-threatening conditions) CBER has long exercised case‑by‑case discretion for complex CGTs, the significance of this announcement is that flexible approach to CMC requirements for CGT is now the norm. It’s intended to create transparency, predictability, and harmonised expectations across CGT reviews. Where sponsors and regulatory affairs teams once had to rely heavily on precedent and experience to determine the best CMC strategy, they now have clear, FDA‑endorsed guidance across three critical areas that consistently pose challenges for CGT development.

The FDA’s updated approach formalises several CMC flexibilities for CGTs across development, commercial release, and process validation. FDA confirms that CGT programs will follow a lifecycle approach, recognising that product and process understanding mature over time. Quality and patient safety remain paramount, but risk‑based strategies may be used to justify staged development. In brief, during clinical development, sponsors are not expected to meet full current Good Manufacturing Practice (21 CFR Part 211) requirements before Phase 2/3 manufacturing, may use evolving process and method validation strategies, and can apply permissive IND‑stage release criteria, with minor manufacturing changes allowed between early and registrational studies when supported by comparability data. For commercial specifications, FDA acknowledges the limited lot numbers typical of CGTs and will consider justified flexibility in setting BLA release specifications, as well as allow post‑approval adjustments to the specifications when manufacturers demonstrate consistent product quality. Finally, in process validation, CBER may permit concurrent release of process performance qualification (PPQ) batches and does not mandate a fixed number of PPQ lots, instead evaluating whether the proposed number of validation batches is appropriate based on overall process understanding. Overall, this flexible approach is meant to support efficient, science-based development of CGT products by improving consistency across review divisions and reducing ambiguity for sponsors. More details on the FDA’s flexible requirements for CGT can be found here.

Bottom line

To support timely patient access, a more flexible approach may sometimes be needed when the modality, indication, or target population does not align neatly with conventional development scenarios. FDA’s January 2026 announcement does not reduce the need for robust CMC; it clarifies how FDA intends to apply existing regulatory flexibility for CGTs with greater transparency and consistency, so sponsors can plan development and BLA strategies with more confidence. The FDA still encourages early engagement with CBER throughout development to help clarify CMC expectations and Boyds can support therapy developers in preparing for and engaging in these interactions to de-risk the overall strategy. Boyds can also support therapy developers by identifying where flexibility may be applied within the CMC package and by building a strong rationale to support the overall submission strategy.

Planning your CMC strategy for a cell or gene therapy? Boyds supports sponsors at every stage of development, from early planning through to BLA submission. Speak to our team to ensure your program is positioned for success.